Literature DB >> 9108425

CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.

R J Soiffer1, D Fairclough, M Robertson, E Alyea, K Anderson, A Freedman, L Bartlett-Pandite, D Fisher, R L Schlossman, R Stone, C Murray, A Freeman, K Marcus, P Mauch, L Nadler, J Ritz.   

Abstract

The appropriate timing of bone marrow transplantation (BMT) for adults with acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) is controversial. Although allogeneic transplantation results in a lower risk of disease recurrence than intensive chemotherapy alone, overall outcome following BMT may not be improved due to the higher incidence of therapy-related fatal complications, frequently as a result of the development of graft-versus-host disease (GVHD). Selective T-cell depletion of donor marrow can reduce the incidence of GVHD and thereby limit transplant-related toxicity. Herein we report the risk of GVHD, incidence of transplant related mortality (TRM), likelihood of disease relapse, and overall survival in adult patients undergoing BMT with CD6 depleted allogeneic marrow for acute leukemia in first remission. Forty-one consecutive allogeneic transplants were performed on patients with acute leukemia and high-risk features (28 AML, 13 ALL) using T12 monoclonal antibody and complement to remove CD6+ T cells from donor marrow. No pre- or posttransplant immune suppressive medications for GVHD prophylaxis were administered. The actuarial estimated risk of grade 2 to 4 acute GVHD was 15% in patients receiving HLA identical grafts. Chronic GVHD developed in five patients. The estimated risk of TRM for patients in first complete remission was 5% at Day +100 and 16% at 2 years. Fatalities attributable to infection with cytomegalovirus or Epstein-Barr virus occurred in only three patients. Estimated probabilities of relapse, overall survival, and event-free survival at 4 years were 25%, 71%, and 63%, respectively. No significant differences in GVHD, TRM, relapse rate, or survival was observed for patients with AML compared with those with ALL. Allogeneic transplantation with CD6 depleted bone marrow is effective in consolidating remissions of high-risk patients with acute leukemia in first remission without excessive toxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108425

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Intestinal graft-versus-host disease: mechanisms and management.

Authors:  Hiroyuki Takatsuka; Tsuyoshi Iwasaki; Takahiro Okamoto; Eizo Kakishita
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance.

Authors:  Marcel van den Brink; Markus Uhrberg; Lorenz Jahn; John F DiPersio; Michael A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

3.  Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.

Authors:  John G Gribben; David Zahrieh; Katherine Stephans; Lini Bartlett-Pandite; Edwin P Alyea; David C Fisher; Arnold S Freedman; Peter Mauch; Robert Schlossman; Lecia V Sequist; Robert J Soiffer; Blossom Marshall; Donna Neuberg; Jerome Ritz; Lee M Nadler
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

Review 4.  Novel strategies for adoptive therapy following HLA disparate transplants.

Authors:  Richard J O'Reilly; Aisha Hasan; Ekaterina Doubrovina; Guenther Koehne; Susan Prockop
Journal:  Best Pract Res Clin Haematol       Date:  2011-09       Impact factor: 3.020

5.  Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.

Authors:  Carolyn A Keever-Taylor; Steven M Devine; Robert J Soiffer; Adam Mendizabal; Shelly Carter; Marcelo C Pasquini; Parameswaran N Hari; Anthony Stein; Hillard M Lazarus; Charles Linker; Steven C Goldstein; Edward A Stadtmauer; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-26       Impact factor: 5.742

Review 6.  Mechanistic approaches for the prevention and treatment of chronic GVHD.

Authors:  Corey S Cutler; John Koreth; Jerome Ritz
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

7.  Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.

Authors:  Emmanuel Zorn; Mehrdad Mohseni; Haesook Kim; Fabrice Porcheray; Allison Lynch; Roberto Bellucci; Christine Canning; Edwin P Alyea; Robert J Soiffer; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

8.  Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.

Authors:  Marcelo C Pasquini; Steven Devine; Adam Mendizabal; Lindsey R Baden; John R Wingard; Hillard M Lazarus; Frederick R Appelbaum; Carolyn A Keever-Taylor; Mary M Horowitz; Shelly Carter; Richard J O'Reilly; Robert J Soiffer
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

9.  Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.

Authors:  Koen van Besien; Rangesh Kunavakkam; Gaby Rondon; Marcos De Lima; Andrew Artz; Betul Oran; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2009-05       Impact factor: 5.742

10.  Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.

Authors:  Ulas D Bayraktar; Marcos de Lima; Rima M Saliba; Molly Maloy; Hugo R Castro-Malaspina; Julianne Chen; Gabriela Rondon; Alexander Chiattone; Ann A Jakubowski; Farid Boulad; Nancy A Kernan; Richard J O'Reilly; Richard E Champlin; Sergio Giralt; Borje S Andersson; Esperanza B Papadopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.